From Needle to Pill: The New Face of Obesity Treatment

Novo's amycretin pill shows big early weight-loss results, hinting at a future beyond injections.

25 Jun 2025

Novo Nordisk may be on the verge of rewriting the rules of obesity treatment with a pill.

Early trial results for amycretin, an oral therapy still in Phase 1 testing, suggest it could challenge the current dominance of injectable treatments. In one study, patients lost roughly 13% of their body weight in just 12 weeks. A separate trial using a weekly injection at higher doses saw weight loss climb to 24.3% over 36 weeks.

Those numbers, released in June, immediately stirred global buzz. So far, the obesity drug boom has centered on injectables like Novo's own semaglutide and Eli Lilly's tirzepatide. Amycretin adds a powerful twist: weight loss results that might one day come in a simple pill.

That convenience could reshape the market. Oral medications are generally easier to take and cheaper to deliver. If amycretin holds up in larger studies, it could lower the barriers to treatment and expand access to millions more patients.

The science behind amycretin uses a dual-hormone approach to better control appetite and metabolism. Novo Nordisk calls the early results "significant," but experts remain cautious. Weight often returns when treatment ends, and long-term outcomes are still unknown.

Cost is another looming question. In the U.S., insurers are already straining under the surge in demand for anti-obesity drugs. Expanding access may require new pricing models or stronger coverage mandates. Neither of those come easy.

Meanwhile, the race is heating up. Eli Lilly is developing its own next-gen drugs, and smaller biotech firms are chasing breakthrough therapies that could upend the landscape again.

If oral options like amycretin prove their worth, the impact could ripple far beyond obesity clinics. Primary care, diabetes treatment, even heart disease management may all shift as doctors reach for pills instead of scalpels.

For now, Novo Nordisk has the spotlight and the momentum. Whether amycretin lives up to its early promise will depend on how it performs in broader trials and how healthcare systems respond. But one thing is clear: the battle for obesity care just got a lot more interesting.